- Home
- AD vs BLTE Comparison
AD vs BLTE Comparison
Compare AD & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AD | BLTE |
|---|---|---|
| Founded | 1983 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.1B |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | AD | BLTE |
|---|---|---|
| Price | $50.07 | $151.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $51.67 | ★ $149.00 |
| AVG Volume (30 Days) | 192.2K | ★ 250.3K |
| Earning Date | 11-07-2025 | 11-10-2025 |
| Dividend Yield | ★ 45.87% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $3,795,787,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $28.22 | N/A |
| P/E Ratio | $278.49 | ★ N/A |
| Revenue Growth | ★ 252.49 | N/A |
| 52 Week Low | $44.03 | $49.00 |
| 52 Week High | $79.17 | $160.55 |
Technical Indicators
Market Signals| Indicator | AD | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 69.59 |
| Support Level | N/A | $115.41 |
| Resistance Level | N/A | $160.55 |
| Average True Range (ATR) | 0.00 | 12.57 |
| MACD | 0.00 | 1.79 |
| Stochastic Oscillator | 0.00 | 79.92 |
Price Performance
Historical ComparisonAbout AD Array Digital Infrastructure Inc. Common Shares
Array Digital Infrastructure, formerly US Cellular, sold its regional wireless operations serving about 4.4 million customers to T-Mobile in August 2025. The firm has agreed to sell most of its remaining spectrum licenses to Verizon and AT&T; however, it will still retain rights to C-band spectrum in several locations after these deals are closed. Array also owns a 5.5% stake in Verizon Wireless' Los Angeles operations and about 4,400 wireless towers.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.